Clinical Trial

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.
Trial Details
NCT Number NCT06558708
Lead Sponsor Gan and Lee Pharmaceuticals, USA
Conditions Type 2 Diabetes
Enrollment 60 participants
Start Date 2024-06-28
Primary Completion 2024-12 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-19